<DOC>
	<DOCNO>NCT00354861</DOCNO>
	<brief_summary>This single centre , three single administration ( Days 1 , 29 57 ) increase dos IMP321 ( 3 , 10 , 30 100 µg ) four cohort 12 subject , single blind , randomize study .</brief_summary>
	<brief_title>A Randomized Phase I Study Hepatitis B Antigen Combined With IMP321</brief_title>
	<detailed_description>In cohort , 8 subject receive hepatitis B antigen ( 10 µg ) IMP321 one dose , 2 subject receive reference hepatitis B antigen ( 10 µg ) alone physiological saline 2 subject receive commercial vaccine Engerix B® ( 20 µg ) . Engerix B® administer intramuscularly . The treatment administer subcutaneously . The four successive cohort volunteer : Cohort A : - 8 subject treat hepatitis B antigen ( 10 µg HbsAg , subtype adw , without alum ) IMP321 ( 3 µg ) , - 2 subject treat hepatitis B antigen ( 10 µg HbsAg , subtype adw , without alum ) physiological saline , - 2 subject treat commercial hepatitis vaccine Engerix B® ( 20 µg HBsAg alum ) . If tolerability cohort acceptable , follow cohort do . Cohort B : - 8 subject treat hepatitis B antigen ( 10 µg HbsAg , subtype adw , without alum ) IMP321 ( 10 µg ) , - 2 subject treat hepatitis B antigen ( 10 µg HbsAg , subtype adw , without alum ) Physiological saline , - 2 subject treat commercial hepatitis vaccine Engerix B® ( 20 µg HBsAg alum ) . If tolerability cohort acceptable , follow cohort do . Cohort C : - 8 subject treat hepatitis B antigen ( 10 µg HbsAg , subtype adw , without alum ) IMP321 ( 30 µg ) , - 2 subject treat hepatitis B antigen ( 10 µg HbsAg , subtype adw , without alum ) physiological saline , - 2 subject treat commercial hepatitis vaccine Engerix B® ( 20 µg HBsAg alum ) . If tolerability cohort acceptable , follow cohort do . Cohort D : - 8 subject treat hepatitis B antigen ( 10 µg HbsAg , subtype adw , without alum ) IMP321 ( 100 µg ) , - 2 subject treat hepatitis B antigen ( 10 µg HbsAg , subtype adw , without alum ) physiological saline - 2 subject treat commercial hepatitis vaccine Engerix B® ( 20 µg HBsAg alum ) . Blood sample collect morning day 1 , 29 , 36 , 57 85 pharmacodynamic evaluation . Monitoring occurrence adverse event ( AE ) , change physical examination , vital sign ( blood pressure , pulse rate , respiration ) , electrocardiogram ( ECG ) clinical laboratory test ( biochemistry , haematology , urinalysis ) perform dose study drug ass safety tolerability .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Aluminum sulfate</mesh_term>
	<criteria>able give write informed consent ; healthy male volunteer age 18 40 year postmenopausal healthy woman age 18 55 year ; body mass index ( weight/height² ) range 18 30 kg/m² ; register French Social Security agreement French Law ( Huriet Law : N° 88.1138 20.12.88 ) biomedical experimentation ; able comply protocol requirement , include overnight stay , blood urine sample collection define protocol ; previously vaccinate Hepatitis B. direct question physical examination evidence clinically significant acute chronic disease , include know suspected HIV , HBV HCV infection ; clinically significant abnormality follow review prestudy laboratory test full physical examination ; receive experimental drug within exclusion period define National Register Healthy Volunteers French Ministry Health ; forfeit freedom administrative legal award guardianship ; unwilling give inform consent ; present positive laboratory test Hepatitis B surface antigen ( HbsAg ) , HBc antibody , HIV 1 2 antibody HCV antibody ; history allergy intolerance study drug ; history serious allergy , asthma , allergic skin rash sensitivity drug ; know suspected alcohol drug abuser ; present positive laboratory test urine drug screening ( opiate , barbiturate , amphetamine , cannabis ) ; undergo surgery donate blood within 1 month prior start study ; take prescribed counter drug ( include antacid drug ) , exception paracetamol ( 3 g per day ) within 1 week prior first dose administration ; receive drug know affect hepatic metabolism like cimetidine , ketoconazole , fluconazole , itraconazole , phenytoin , rifampicin , rifabutin within 1 month prior first dose administration ; receive drug know affect renal tubular secretion like probenecid , betalactam antibiotic within 2 week prior first dose administration ; present clinical condition prior therapy , opinion investigator , make subject unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>IMP321</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>